


Presently Pending Claims

Language to be added has been **bolded and underlined**, while language to be deleted has been ~~**bolded and striken-through**~~.


1-20. (Canceled)

21. (Currently amended) A compound represented by the structural formula I



or a pharmaceutically acceptable salt ~~or solvate~~ thereof; wherein:

R¹ is



R² is arylalkyl;

R³ is selected from the group consisting of 6-membered heteroaryl, and 6-membered heteroaryl-N-oxide, wherein said 6-membered heteroaryl or heteroaryl-N-oxide is pyrimidine or pyrimidine-N-oxide respectively, each of which is optionally substituted with 1-4 substituents which can be the same or different and are independently selected from the group consisting of R¹¹, R¹², R¹³, R¹⁴ and R¹⁵;

R⁴ is 1-3 substituents selected from the group consisting of H, halo, alkyl, haloalkyl, alkoxy, cycloalkyl, amide, CF₃, OCF₃, aryl, heteroaryl, -XR⁷, -CN, -CO₂H, -CO₂R²², R⁸-aryl(C₁-C₆)alkyl-, R⁸-heteroaryl(C₁-C₆)alkyl-, -C(O)NR²¹R²², -C(O)NH₂, wherein R⁴ can be the same or different and is independently selected when there is more than one R⁴ present;

R⁷ is selected from the group consisting of aryl, substituted aryl, heteroaryl, alkyl, haloalkyl and cycloalkyl;

R^8 is 1, 2 or 3 substituents selected from the group consisting of H, halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, $-CF_3$, $-OCF_3$, $CH_3C(O)-$, $-CN$, CH_3SO_2- ,

CF_3SO_2- and $-NH_2$, wherein R^8 can be the same or different and is independently selected when there are more than one R^8 present;

R^9 , R^{10} and B can be the same or different and are each independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, and $-(C_1-C_6)$ haloalkyl;

R^{11} and R^{12} can be the same or different and are each independently selected from the group consisting of (C_1-C_6) alkyl, $-(C_1-C_6)$ haloalkyl, halogen, $-NR^{19}R^{20}$, $-OH$, CF_3 , $-OCH_3$, $-O$ -acyl, and $-OCF_3$;

R^{13} is selected from the group consisting of hydrogen, R^{11} , H, phenyl, $-NO_2$, $-CN$, $-CH_2F$, $-CHF_2$, $-CHO$, $-CH=NOR^{19}$, pyridyl-N-oxide, pyrimidinyl, pyrazinyl, $N(R^{20})CONR^{20}R^{21}$, $-NHCONH(chloro-(C_1-C_6)alkyl)$, $-NHCONH((C_3-C_{10})-cycloalkyl(C_1-C_6)alkyl)$, $-NHCO(C_1-C_6)alkyl$, $-NHCOCF_3$, $-NHCOCF_3$, $-NHSO_2N((C_1-C_6)alkyl)_2$, $-NHSO_2(C_1-C_6)alkyl$, $-N(SO_2CF_3)_2$, $-NHCO_2(C_1-C_6)alkyl$, $(C_3-C_{10})cycloalkyl$, $-SR^{22}$, $-SOR^{22}$, $-SO_2R^{22}$, $-SO_2NH(C_1-C_6)alkyl$, $-OSO_2(C_1-C_6)alkyl$, $-OSO_2CF_3$, hydroxy $(C_1-C_6)alkyl$, $-CONR^{19}R^{20}$, $-CON(CH_2CH_2-O-CH_3)_2$, $-OCONH(C_1-C_6)alkyl$, $-CO_2R^{19}$, $-Si(CH_3)_3$ and $-B(OC(CH_3)_2)_2$;

R^{14} is selected from the group consisting of $(C_1-C_6)alkyl$, $-(C_1-C_6)haloalkyl$ $-NH_2$ and R^{15} -phenyl;

R^{15} is 1-3 substituents selected from the group consisting of hydrogen, $(C_1-C_6)alkyl$, $-(C_1-C_6)haloalkyl$, $-CF_3$, $-CO_2R^{20}$, $-CN$, $(C_1-C_6)alkoxy$ and halogen; wherein R^{15} can be the same or different and is independently selected when there are more than one R^{15} present;

R^{19} , R^{20} and R^{21} can each be the same or different and are each independently selected from the group consisting of H, $(C_1-C_6)alkyl$ and $(C_3-C_6)cycloalkyl$;

R^{22} is selected from the group consisting of $(C_1-C_6)alkyl$, $-(C_1-C_6)haloalkyl$, $(C_2-C_6)hydroxyalkyl$, $(C_2-C_6)alkylene$, $(C_3-C_6)cycloalkyl$, aryl and aryl $(C_1-C_6)alkyl$;































A is selected from the group consisting of H, $(C_1-C_6)alkyl$, and $(C_2-C_6)alkenyl$.





































M is aryl optionally substituted with R^4 ; and





































X is selected from the group consisting of CH_2 , SO_2 , SO , S , and O , with the following proviso:

























when R^1 is phenyl, or naphthyl, R^2 cannot be H, $-(C_1-C_6)alkyl$ or $-C(O)-(C_1-C_6)alkyl$.

22. (Currently amended) A compound having the structural formula I according to claim 21 or a pharmaceutically acceptable salt ~~or solvate~~ thereof, wherein R^9 , R^{10} and B are H, A is $-CH_3$, and R^1 , R^2 and R^3 are as defined in the following table:










#	R^1	R^2	R^3
8			
9			
10			
11			
12			
14			
17			
18			
19			
20			





































21			
22			
23			
24			
25			
26			
27			
28			
29			
31			
32			
33			

34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
50			


59			
60			
61			
63			
65			
66			
67			
68			

23. (Currently amended) A compound according to claim 22 or a pharmaceutically acceptable salt thereof, wherein R¹, R² and R³ each represent:


#	R ¹	R ²	R ³
10			
11			
12			

14			
17			
28			
29			
31			
36			
37			
39			
40			
50			
61			
68			

24. (Currently amended) A compound according to claim 23 represented by the structural formulae:



and



or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

25. (Currently amended) A pharmaceutical composition comprising one or more compounds of claim 21 or a pharmaceutically acceptable salt thereof.

26. (Currently amended) A pharmaceutical composition comprising one or more compounds of claim 24 or a pharmaceutically acceptable salt thereof.

27. (Previously presented) The pharmaceutical composition according to claim 25 further comprising one or more pharmaceutically acceptable carriers.

28. (Previously presented) The pharmaceutical composition according to claim 26 further comprising one or more pharmaceutically acceptable carriers.

29. (Currently amended) The pharmaceutical composition according to claim 25, wherein said pharmaceutical composition contains a therapeutically effective

28. (Previously presented) The pharmaceutical composition according to claim 26 further comprising one or more pharmaceutically acceptable carriers.

29. (Currently amended) The pharmaceutical composition according to claim 25, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds or a pharmaceutically acceptable salt ~~or~~ **solvate** thereof.

30. (Currently amended) The pharmaceutical composition according to claim 26, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds or a pharmaceutically acceptable salt ~~or~~ **solvate** thereof.

31-40. (Canceled)